US 11,718,603 B2
CDK2 inhibitors
Douglas Carl Behenna, San Juan Capistrano, CA (US); Kevin Daniel Freeman-Cook, San Diego, CA (US); Robert Louis Hoffman, San Marcos, CA (US); Asako Nagata, San Diego, CA (US); Sacha Ninkovic, San Diego, CA (US); and Scott Channing Sutton, San Diego, CA (US)
Assigned to PFIZER INC., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Apr. 20, 2021, as Appl. No. 17/235,836.
Application 17/235,836 is a continuation of application No. 16/774,786, filed on Jan. 28, 2020, granted, now 11,014,911.
Claims priority of provisional application 62/959,042, filed on Jan. 9, 2020.
Claims priority of provisional application 62/799,455, filed on Jan. 31, 2019.
Prior Publication US 2021/0261530 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/12 (2006.01); A61P 35/00 (2006.01); C07D 413/12 (2006.01)
CPC C07D 403/12 (2013.01) [A61P 35/00 (2018.01); C07D 413/12 (2013.01); C07B 2200/07 (2013.01)] 21 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof, wherein:
R1 is -L1-(5-10 membered heteroaryl) or -L1-(C6-C12 aryl), where said 5-10 membered heteroaryl or C6-C12 aryl is optionally substituted by one or more R4;
R2 and R3 are independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, -L2-(C3-C7 cycloalkyl) or -L2-(4-7 membered heterocyclyl), where each said C1-C6 alkyl and C1-C6 fluoroalkyl is optionally substituted by one or more R5 and each said C3-C7 cycloalkyl and 4-7 membered heterocyclyl is optionally substituted by one or more R6; or
R2 and R3 are taken together with the N-atom to which they are attached to form a 4-6 membered heterocyclyl optionally containing an additional heteroatom selected from O, N(R7) and S(O)q as a ring member, where said 4-6 membered heterocyclyl is optionally substituted by one or more R8;
each L1 and L2 is independently a bond or a C1-C2 alkylene optionally substituted by one or more R9;
each R4 is independently F, Cl, OH, CN, NR10R11, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, C3-C8 cycloalkyl, C(O)NR10R11, SO2R12, SO(═NH)R12 or SO2NR10R11; where each C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by one or more R13;
each R5 is independently OH, C1-C4 alkoxy or NR10R11;
each R6 is independently F, OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy or NR10R11 where each C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by one or more R13;
R7 is H, C1-C4 alkyl or C(O)-C1-C4 alkyl;
each R8 is independently F, OH, C1-C4 alkyl, C1-C4 alkoxy or CN;
each R9 is independently F, OH or C1-C2 alkyl;
each R10 and R11 is independently H or C1-C4 alkyl;
each R12 is C1-C4 alkyl or C3-C6 cycloalkyl;
each R13 is independently OH, C1-C4 alkoxy or NR14R15;
each R14 and R15 is independently H or C1-C4 alkyl; and
q is 0, 1 or 2.